Hyaluronate compositions
View Patent ↗The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for malting and using the same.
1. A composition suitable for topical administration to a mammalian subject, the composition comprising, by mass, from about 0.05% to about 5% of a sodium hyaluronate blend of at least three types of sodium hyaluronate with distinct molecular weight ranges and a pharmaceutically acceptable excipient,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons, and
wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons;
and wherein the pharmaceutically acceptable excipient is predominantly in the liquid phase at ambient temperature.
2. The composition according to claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of water, an alcohol, an oil, glycerin, polyethylene glycol, lanolin, petrolatum, wax, and poloxamer.
3. The composition according to claim 2 , wherein the pharmaceutically acceptable excipient is alcohol selected from the group consisting of ethanol, benzyl alcohol, isopropyl alcohol, octyldodecanol, cetostearyl alcohol, and lanolin alcohol.
4. The composition according to claim 3 , wherein the ratio of the mass of water to the total mass of the composition is about 99.235%.
5. The composition according to claim 2 , wherein the pharmaceutically acceptable excipient is oil selected from the group consisting of almond oil, castor oil, corn oil, cottonseed oil, light mineral oil, mineral oil, olive oil, peanut oil, polyoxyl 35 castor oil, sesame oil, soybean oil, and sunflower oil.
6. The composition according to claim 2 , wherein the pharmaceutically acceptable excipient is water.
7. The composition of claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 60% to about 99.9%.
8. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 90.0% to about 99.9%.
9. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 92.5% to about 99.8%.
10. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 95.0% to about 99.7%.
11. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 97.5% to about 99.6%.
12. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 98.5% to about 99.5%.
13. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 99.0% to about 99.4%.
14. The composition according to claim 6 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 99.2% to about 99.3%.
15. The composition of claim 1 , wherein the composition further comprises an antifungal agent.
16. The composition according to claim 15 , wherein the antifungal agent is selected from the group consisting of clioquinol, haloprogin, miconazole nitrate, povidone-iodine, tolnaftate, ketoconazole, undecylenic acid, butoconazole and clotrimazole.
17. The composition according to claim 16 , wherein the antifungal agent is clotrimazole.
18. The composition according to claim 1 , wherein the composition further comprises an antibiotic.
19. The composition according to claim 18 , wherein the antibiotic is selected from the group consisting of bacitracin, bacitracin zinc, chlortetracycline hydrochloride, neomycin sulfate, clindamycin, erythromycin, and tetracycline hydrochloride.
20. The composition according to claim 1 , wherein the composition further comprises an anti-acne agent.
21. The composition according to claim 20 , wherein the anti-acne agent is selected from the group consisting of benzoyl peroxide, resorcinol, resorcinol monoacetate, salicylic acid, sulfur, adapalene, alitretinoin, etretinate, isotretinoin, tazarotene, and tretinoin.
22. The composition according to claim 21 , wherein the anti-acne agent is benzoyl peroxide.
23. The composition according to claim 22 , wherein the ratio of the mass of benzoyl peroxide to the total mass of the composition ranges from about 2.5% to about 10%.
24. The composition according to claim 1 , wherein the composition further comprises an antiviral agent.
25. The composition according to claim 1 , wherein the composition has an apparent viscosity of from about 10,000 centipoise to about 300,000 centipoise.
26. The composition according to claim 1 , wherein the pH of the composition is from about 4 to about 8.
27. The composition according to claim 1 , wherein the pharmaceutically acceptable excipient comprises white petrolatum.
28. The composition according to claim 27 , wherein the composition further comprises butylated hydroxytoluene.
29. The composition according to claim 27 , wherein the composition further comprises butylated hydroxyanisole.
30. The composition according to claim 1 , wherein the composition further comprises butylated hydroxytoluene.
31. The composition according to claim 1 , wherein the composition further comprises butylated hydroxyanisole.
32. The composition according to claim 1 , wherein the composition further comprises one or more ceramides.
33. The composition according to claim 1 , wherein the composition further comprises a corticosteroid.
34. The composition according to claim 33 , wherein the corticosteroid is selected from the group consisting of betamethasone valerate, betamethasone dipropionate, dexamethasone acetate, dexamethasone sodium phosphate, hydrocortisone, hydrocortisone acetate, and hydrocortisone butyrate.
35. A composition suitable for maintaining or enhancing the moisture of skin, the composition comprising, by mass, at least about 80% water; a blend of at least three types of sodium hyaluronate with distinct molecular weight ranges,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons, and
wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons;
one or more preservatives; one or more thickening agents; and one or more bases;
wherein the ratio of the mass of the sodium hyaluronate blend to the total mass of the composition is about 0.1%.
36. The composition of claim 35 , wherein the one or more preservatives are selected from the group consisting of methylparaben, propylparaben, edetate sodium, benzalkonium chloride, and benzyl alcohol.
37. The composition of claim 36 , wherein the one or more preservatives comprise methylparaben.
38. The composition of claim 36 , wherein the one or more preservatives comprise propylparaben.
39. The composition of claim 36 , wherein the one or more preservatives comprise methylparaben and propylparaben.
40. The composition of claim 36 , wherein the one or more thickening agents are selected from the group consisting of carbomer 940, methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, one or more alginates, acacia, and one or more chitosans.
41. The composition of claim 40 , wherein the one or more thickening agents comprise carbomer 940.
42. The composition of claim 35 , wherein the one or more bases are selected from the group consisting of trolamine, sodium hydroxide, sodium bicarbonate, potassium hydroxide, magnesium hydroxide, calcium hydroxide, ammonium hydroxide, and potassium bicarbonate.
43. The composition of claim 42 , wherein the one or more bases comprise trolamine.
44. The composition of claim 35 , wherein the pH of the composition is between about 4 and about 8.
45. The composition of claim 35 , wherein the composition has an absorbance of not more than 0.1 at 600 nm and a path of 1.0 cm and wherein the composition has a viscosity measured at temperature of 25 degree Celsius of not less than 5,000 centipoise and not more than 100,000 centipoise.
46. A composition suitable for maintaining or enhancing the moisture of skin, the composition comprising, by mass, at least about 95% water; 0.1% of a blend of at least three types of sodium hyaluronate with distinct molecular weight ranges,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons,
and wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons;
one or more preservatives; one or more thickening agents; and one or more bases;
wherein the composition has an absorbance of not more than 0.1 at 600 nm and a path of 1.0 cm and wherein the composition has a viscosity measured at temperature of 25 degree Celsius of not less than 11,000 centipoise and not more than 18,000 centipoise.
47. A composition suitable for maintaining or enhancing the moisture of skin, the composition consisting essentially of, by mass, at least about 99% water; about 0.1% of a blend of at least three types of sodium hyaluronate with distinct molecular weight ranges,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons,
and wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons;
one or more preservatives; one or more thickening agents; and one or more bases.
48. A composition suitable for maintaining or enhancing the moisture of skin, the composition consisting essentially of, by mass:
about 0.1% of a blend of at least three types of sodium hyaluronate with distinct molecular weight ranges,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons,
wherein from about 0.1 wt % to about 5 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons,
and wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate blend in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons;
about 0.2% methylparaben;
about 0.02% propylparaben;
about 0.3% carbomer 940;
about 0.15% trolamine; and
about 99.23% water.
49. A method for treating a skin disorder on a mammalian subject, said method comprising administering to said subject an effective amount of the composition according to claim 1 , wherein the skin disorder is selected from the group consisting of eczema, dermatitis, atopic dermatitis, xerosis, psoriasis, inflammation, diaper rash, fungal infection and acne.
50. The method according to claim 49 , wherein the composition is administered at least once per day.
51. The method according to claim 50 , wherein the composition is administered at least twice per day.
52. The method according to claim 51 , wherein the composition is administered three times per day.
53. A process for manufacturing the composition according to claim 1 , the process comprising the steps of:
(a) admixing one or more preservatives, sodium hyaluronate, and one or more thickening agents to form a pre-water mixture;
(b) admixing one or more bases and water to form a water mixture;
(c) admixing the pre-water mixture and the water mixture to form a post-water mixture; and
(d) homogenizing the post-water mixture to form the composition.
54. The process of claim 53 , wherein step (a) comprises admixing methylparaben, propylparaben, sodium hyaluronate, and carbomer 940 in an approximate ratio, by mass, of 0.2:0.02:0.1:0.3 to form the pre-water mixture.
55. The process of claim 53 , wherein step (b) comprises admixing trolamine and water in an approximate ratio, by mass, of 0.15:99.23 to form the water mixture.
56. The process of claim 53 , wherein step (c) comprises admixing the pre-water mixture and the water mixture in an approximate ratio, by mass, of 0.62:99.38, to form a post-water mixture.